AGT and COVID-19: Two of the identified GPCR-fAABs, observed in over 90% of the investigated COVID-19 patient sera (29/31), were directed against receptors of RAS, namely the angiotensin II AT1 receptor and the angiotensin (1–7) MAS receptor.